Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 0.7% – Here’s What Happened

Tiziana Life Sciences Ltd (NASDAQ:TLSA)’s share price fell 0.7% on Monday . The stock traded as low as $1.35 and last traded at $1.40. 114,646 shares were traded during mid-day trading, a decline of 53% from the average session volume of 245,140 shares. The stock had previously closed at $1.41.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TLSA. Wall Street Zen downgraded shares of Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings downgraded shares of Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Tiziana Life Sciences Trading Down 0.7%

The business has a fifty day moving average price of $1.34 and a two-hundred day moving average price of $1.46.

Tiziana Life Sciences (NASDAQ:TLSA) last announced its quarterly earnings data on Friday, May 1st. The company reported ($0.28) EPS for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rachor Investment Advisory Services LLC purchased a new position in Tiziana Life Sciences during the fourth quarter valued at approximately $25,000. Cubist Systematic Strategies LLC purchased a new position in Tiziana Life Sciences during the first quarter valued at approximately $25,000. Marshall Wace LLP purchased a new position in Tiziana Life Sciences in the second quarter valued at about $39,000. HRT Financial LP purchased a new position in Tiziana Life Sciences in the fourth quarter valued at about $36,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Tiziana Life Sciences in the fourth quarter valued at about $59,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.